Literature DB >> 21132841

New aspects of the Slug Mucosal Irritation assay: predicting nasal stinging, itching and burning sensations.

Joke Lenoir1, Els Adriaens, Jean-Paul Remon.   

Abstract

Stinging, itching and/or burning (SIB) sensations cannot be detected by animal tests or in vitro models. In the past, the Slug Mucosal Irritation (SMI) assay demonstrated a relation between an increased mucus production in slugs and an elevated incidence of SIB sensations in humans. A new 1-day SMI test procedure was developed focusing on the prediction of these short-term sensations. The objective of this study was to verify whether this new procedure is capable predicting mucosal tolerance of several marketed nasal formulations using the slug Arion lusitanicus. Irritation and tissue damage were quantified with a 5-day repeated exposure study by means of the mucus produced and proteins and enzymes released. The new protocol predicted SIB sensations by means of mucus production. The effects of six liquid nasal formulations were tested with both protocols, while five physiologic saline solutions were only tested with the new protocol to optimize it. None of the tested liquid nasal formulations resulted in tissue damage; however, exposure to the different formulations had a clear effect on the mucus production of the slugs and moderate discomfort was observed in some cases. These effects were due to the active ingredient, the presence of benzalkonium chloride as a preservative or the hyperosmolality of the formulation. For the most part results agreed with clinical data found in literature. It was concluded that the SMI assay, and the new 1-day protocol in particular, is a good tool to predict nasal clinical discomfort.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132841     DOI: 10.1002/jat.1610

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  4 in total

1.  Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.

Authors:  Richard Kendall; Joke Lenoir; Stephen Gerrard; Rebekah L Scheuerle; Nigel K H Slater; Catherine Tuleu
Journal:  Pharm Res       Date:  2017-02-13       Impact factor: 4.200

2.  The safety profile of Bald's eyesalve for the treatment of bacterial infections.

Authors:  Blessing O Anonye; Valentine Nweke; Jessica Furner-Pardoe; Rebecca Gabrilska; Afshan Rafiq; Faith Ukachukwu; Julie Bruce; Christina Lee; Meera Unnikrishnan; Kendra P Rumbaugh; Lori A S Snyder; Freya Harrison
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

3.  Potential Mucosal Irritation Discrimination of Surface Disinfectants Employed against SARS-CoV-2 by Limacus flavus Slug Mucosal Irritation Assay.

Authors:  Marco Alfio Cutuli; Antonio Guarnieri; Laura Pietrangelo; Irene Magnifico; Noemi Venditti; Laura Recchia; Katia Mangano; Ferdinando Nicoletti; Roberto Di Marco; Giulio Petronio Petronio
Journal:  Biomedicines       Date:  2021-04-14

4.  Nasal Powder Formulations: In-Vitro Characterisation of the Impact of Powders on Nasal Residence Time and Sensory Effects.

Authors:  Marie Trenkel; Regina Scherließ
Journal:  Pharmaceutics       Date:  2021-03-13       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.